CycloSal-PMEA and cycloAmb-PMEA: Potentially new phosphonate prodrugs based on the cyclosal-pronucleotide approach

Journal of Medicinal Chemistry

Volumn 48, Issue 25, 2005, Pages 8079-8086

  Meier, Chris ^a   Görbig, Ulf ^a   Müller, Christian ^a   Balzarini, Jan ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOBENZYL ALCOHOL; ACETYLCHOLINESTERASE; ADEFOVIR; ANTIRETROVIRUS AGENT; BENZYL ALCOHOL DERIVATIVE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; NUCLEOSIDE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PRODRUG; SALIGENIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHOLINESTERASE INHIBITION; CONTROLLED STUDY; DRUG HYDROLYSIS; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; ESTERIFICATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; LIPOPHILICITY; MASS SPECTROMETRY; PARTITION COEFFICIENT; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SERUM;

ACETYLCHOLINESTERASE; ADENINE; ANTI-HIV AGENTS; BENZYL ALCOHOLS; BUTYRYLCHOLINESTERASE; CELL LINE; CHOLINESTERASE INHIBITORS; HIV-1; HIV-2; HUMANS; HYDROLYSIS; MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHONIC ACIDS; PRODRUGS; SPECTROPHOTOMETRY, ULTRAVIOLET; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 29144464769     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050641a     Document Type: Article

References (33)

1. (a) Naesens, L.; Balzarini, J.; De Clercq, E. Therapeutical potential of PMEA as an antiviral drug. Med. Virol. 1994, 4, 147-159.
2. (b) De Clercq, E. Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines. Biochem. Pharmacol. 1991, 42, 963-972.
3. (c) De Clercq, E.; Holy, A.; Rosenberg, I.; Sakuma, T.; Balzarini, J.; Maudgal, P. C. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986, 323, 464-467.
4. (d) De Clercq, E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002, 55, 1-13.
5. (e) Arimilli, M. N.; Dougherty, J. P.; Cundy K. C.; Bischofberger, N. Orally bioavailable acyclic nucleoside phosphonate prodrugs: Adefovir dipivoxil and Ms(POC)PMPA. In Advances in Antiviral Drug Design; De Clercq E., Ed.; JAI Press: Stamford, CT, 1999; pp 69-91.
6. (f) Robbins, B. L.; Srinivas, R. V.; Kim, C.; Bischofberger, N.; Fridland, A. Anti-Human Immunodeficiency Virus Activity and Cellular Metabolism of a Potential Prodrug of the Acyclic Nucleoside Phosphonate 9-R-(2-Phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl) PMPA. Antimicrob. Agents Chemother. 1998, 42, 612-617.
7. Srinivas, R. V.; Robbins, B. L.; Connelly, M. C.; Gong, Y. F.; Bischofberger, N.; Fridland, A. Metabolism an in vitro Antiretroviral Activities of Bis(Pivaloyloxymethyl)-Prodrugs of Acyclic Nucleoside Phosphonates. Antimicrob. Agents Chemother. 1993, 37, 2247-2250.
8. Starrett Jr., J. E.; Tortolani, D. R.; Hitchcock, M. J. M.; Martin, J. C.; Mansuri, M. M. Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloylosymethyl)9-(2-phosphonylmethoxyethyl)adenine. Antiviral Res. 1992, 19, 267-273.
9. Benzaria, S.; Pélicano, H.; Johnson, R.; Maury, G.; Imbach, J. L.; Aubertin, A. M.; Obert, G.; Gosselin, G. Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-(2-phosphonometoxy)ethyladenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. J. Med. Chem. 1996, 39, 4958-4965.
10. (a) Meier, C. CycloSal-pronucleotides - design of chemical trojan horses. Mini Rev. Med. Chem. 2002, 2, 219-234.
11. (b) Meier, C.; Ruppel, M.; Vukadinovic, D.; Balzarini, J. "Lock-in"-cycloSal-pronucleotides - a new generation of chemical trojan horses. Mini Rev. Med. Chem. 2004, 4, 383-394.
12. (c) Meier, C. CycloSal-pronucleotides - design of the concept, chemistry and antiviral acticity. In Advances in Antiviral Drug Design; De Clercq, E., Ed.; JAI Press: Stamford, CT, 2004; Vol. 4, pp 147-213.
13. (a) Meier, C.; Lorey, M.; De Clercq, E.; Balzarini, J. CycloSal-2′,3′-dideoxy-2′,3′-didehydrothymidine monophosphate (cycloSal-d4TMP): Synthesis and antiviral evaluation of a new d4TMP delivery system. J. Med. Chem. 1998, 41, 1417-1427.
14. (b) Ducho, C.; Wendicke, S.; Görbig, U.; Balzarini, J.; Meier, C. 3,5-tert-Butyl-6-fluoro-cycloSal-d4TMP - a pronucleotide with a highly optimized masking group. Eur. J. Org. Chem. 2003, 4786-4791.
15. Meier, C.; Lomp, A.; Meerbach, A.; P. Wutzier, P. CycloSal-BVDUMP pronucleotides - How to convert an anti-EBV-inactive nucleoside analogue into a bioactive compound. J. Med. Chem. 2002, 45, 5157-5172.
16. Meier, C.; Ruppel, M.; Vukadinovic, D.; Balzarini, J. Second generation of cycloSal-pronucleotides with esterase-cleavable sites - the "lock-in"-concept. Nucl., Nucl., Nucleic Acids 2004, 89-115.
17. Puech, F.; Gosselin, G.; Lefebvre, I.; Pompom, A.; Aubertin, A.-M.; Kim, A.; Imbach, J.-L. Intracellular delivery of nucleoside monophosphates through a reductase-mediated activation process. Antiviral Res. 1993, 22, 155-174.
18. 5. Chem. Lett. 1980, 435-438;
19. (b) Serafinowska, H. T.; Ashton, A. J.; Bailey, S.; Harnden, M. R.; Jackson, S. M.; Sutton, D. Synthesis and in vivo evaluation of prodrugs of 9-[2-(phosphonomethoxy)ethoxy]adenine. J. Med. Chem. 1995, 38, 1372-1379.
20. 450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J. Am. Chem. Soc. 2004, 126, 5154-5163.
21. Balzarini, J.; Cools, J. M.; De Clercq, E. Estimation of the lipophilicity of anti-HIV nucleoside analogues by determination of the partition coefficient and retention time on a LiChrosphere 60 RP-8 HPLC column. Biochem. Biophys. Res. Commun. 1989, 158, 413-422.
22. (a) Balzarini, J.; Aquaro, S.; Knispel, T.; Rampazzo, C.; Bianchi, V.; Perno, C.-F.; De Clercq, E.; Meier, C. Cyclosaligenyl-2′,3′- didehydro-2′,3′-dideoxythymidine monophosphate: Efficient intracellular delivery of d4TMP. Mol. Pharmacol. 2000, 58, 928-935.
23. (b) Balzarini, J.; Naesens, L.; Aquaro, S.; Knispel, T.; Perno, C.-F.; De Clercq, E.; Meier, C. Intracellular metabolism of cycloSaligenyl 3′-azido-2′,3′-dideoxythymidine monophosphate, a prodrug of 3′-azido-2′,3′-dideoxythymidine (Zidovudine). Mol. Pharmacol. 1999, 56, 1354-1361.
24. Cox, Jr., J. R.; Ramsay, B. Mechanisms of nucleophilic substitution in phosphate esters. Chem. Rev. 1964, 64, 317-352.
25. Hudson, R. F.; Keay, L. The hydrolysis of phosphonate esters. J. Chem. Soc. 1956, 2463-2469.
26. Westheimer, F. H.; Huang, S.; Covitz, F. Rates and mechanisms of hydrolysis of esters of phosphorous acid. J. Am. Chem. Soc. 1988, 110, 181-185.
27. Meier, C.; Renze, J.; Ducho, C.; Balzarini, J. CycloSal-d4TMP pronucleotides - Structural variations, mechanistic insights and antiviral activity. Curr. Top. Med. Chem. 2002, 2, 1111-1121.
28. Balatore, C.; McGuigan, C.; De Clercq, E.; Balzarini, J. Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA. Bioorg. Med. Chem. Lett. 2001, 11, 1053-1056.
29. Ducho, C.; Balzarini, J.; Meier, C. Noninhibition of acetylcholinesterase by cycloSal-nucleotides. Nucl., Nucl., Nucleic Acids 2003, 22, 841-843.
30. Meier, C.; Ducho, C.; Görbig, U.; Esnouf, R.; Balzarini, J. Interaction of eycloSal-pronucleotides with cholinesterases from different origins - A structure-activity relationship. J. Med. Chem. 2004, 47, 2839-2852.
31. Holy, A.; Rosenberg, I. Synthesis of 9-[2-(phosphonylmethoxy)-ethyl] adenine and related compounds. Collect. Czech. Chem. Commun. 1987, 52, 2801-2809.
32. Bronson, J. J.; Ghazzouli, I., Hitchcock, M. J. M.; Webb, R. R., II.; Martin, J. C. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine. J. Med Chem. 1989, 32, 1457-1463.
33. Popovic, M.; Sarngadharan, M. G.; Read, E.; Gallo, R. C. Detection, Isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984, 224, 497-500.